Cargando…

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

As a new-generation CDK inhibitor, a CDK4/6 inhibitor combined with endocrine therapy has been successful in the treatment of advanced estrogen receptor–positive (ER+) breast cancer. Although there has been overall progress in the treatment of cancer, drug resistance is an emerging cause for breast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhen, Zou, Wei, Zhang, Ji, Zhang, Yunjiao, Xu, Qi, Li, Siyuan, Chen, Ceshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751736/ https://www.ncbi.nlm.nih.gov/pubmed/33364954 http://dx.doi.org/10.3389/fphar.2020.580251

Ejemplares similares

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
por: Gomes, Inês, et al.
Publicado: (2023)

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
por: Roncato, Rossana, et al.
Publicado: (2022)

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
por: Ji, Jing, et al.
Publicado: (2023)

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
por: Cordani, Nicoletta, et al.
Publicado: (2023)

A mass balance study of [(14)C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
por: Zhang, Hua, et al.
Publicado: (2023)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
por: Sun, Chao-Yue, et al.
Publicado: (2022)

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
por: Huang, Jinyao, et al.
Publicado: (2022)

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
por: Pandey, Kamal, et al.
Publicado: (2019)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma
por: Xia, Zhong-Kun, et al.
Publicado: (2021)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database
por: Prevost, Rachel, et al.
Publicado: (2023)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

The methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism is associated with breast cancer subtype susceptibility in southwestern China
por: Li, Zhen, et al.
Publicado: (2021)

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
por: Dong, Chao, et al.
Publicado: (2021)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer
por: Zhu, Xiang, et al.
Publicado: (2023)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
por: Liang, Hanzhi, et al.
Publicado: (2022)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Scheidemann, Erin R., et al.
Publicado: (2021)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
por: Liu, Jingyi, et al.
Publicado: (2018)

Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells via Inhibiting CDK4-RB Pathway
por: Wang, Yong, et al.
Publicado: (2020)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Luminal Conversion and Immunoregulation by Probiotics
por: Ganesh, Bhanu Priya, et al.
Publicado: (2015)

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer
por: Zhu, Wenge, et al.
Publicado: (2023)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
por: Main, Sasha C., et al.
Publicado: (2022)

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
por: Raimondi, Lucrezia, et al.
Publicado: (2021)

Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
por: Wang, Qingfei, et al.
Publicado: (2019)

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
por: Jin, Xi, et al.
Publicado: (2020)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
por: Umfress, Alan, et al.
Publicado: (2022)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
por: Mouron, Silvana, et al.
Publicado: (2021)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pp8onld0fqhd0uavskfr4vd6fs